NovoSeven® RT enters the bloodstream and targets the site of injury. It can support thrombin generation for patients with congenital hemophilia (FVIII or FIX deficiency) who have inhibitors to replacement factor.1,2
Works at the site of injury.1
NovoSeven® RT is recombinant Factor VIIa. It can support thrombin generation for patients with congenital hemophilia A or B with inhibitors.1,2

NovoSeven® RT resolves bleeds in CHwI by allowing the formation of a stable hemostatic plug.


Targeting


Activation
NovoSeven® RT binds directly to activated platelets, activating FX to produce FXa.1,2 FXa complexes with other factors to convert prothrombin to thrombin.1


Clot formation
The burst of thrombin leads to the formation of fibrin, which is the foundation of a stable clot.1


Bleed resolution
NovoSeven® RT resolves the bleed by allowing the formation of a stable hemostatic plug.1
The only recombinant bypassing agent not made from human serum or human proteins.1
NovoSeven® RT is manufactured in cell lines considered to be free of viruses, and undergoes additional steps to help ensure safety and purity. Recombinant factor products minimize the possibility of viral contamination.1,3


Approved for bleed management and
surgical use in 4 indicated disorders.

Learn about a rare and
serious condition.
